The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat
Current antipsychotics are ineffective at treating the negative and cognitive symptoms of schizophrenia, so there is a substantial need to develop more effective therapeutics for this debilitating disorder. The type II metabotropic glutamate receptor (mGluR2/3) is a novel, potential therapeutic target requiring evaluation in appropriate preclinical models of schizophrenia.
This study evaluated the potent, selective mGluR2/3 agonist, LY379268, on the behavioural deficits induced by rearing rat pups in social isolation from weaning, a neurodevelopmental model of schizophrenia, to investigate its antipsychotic potential.
Male Lister Hooded rats were weaned on post-natal day 23–25 and either group-housed (3–4 per cage) or isolation-reared for 6 weeks. At subsequent weekly intervals, animals received acute systemic injection of either vehicle or LY379268 (1 mg/kg; i.p.) 30 min prior to recording locomotor activity in a novel arena, novel object recognition, pre-pulse inhibition of acoustic startle and conditioned emotional response paradigms.
Isolation rearing induced locomotor hyperactivity, deficits in novel object recognition, conditioned emotional behaviour and attenuated the magnitude of the initial acoustic startle response in the PPI paradigm compared to that of group-housed controls. LY379268 reversed the isolation-induced locomotor hyperactivity, the object recognition deficit, and restored startle responses in isolated animals, whilst having no effect on conditioned emotional response impairments.
These data show that LY379268 can reverse some, but not all, post-weaning social isolation-induced changes which have translational relevance to core symptom defects in schizophrenia and support a potential therapeutic role of mGluR2/3 agonists in its treatment.
KeywordsSchizophrenia Post-weaning social isolation mGluR2/3 Glutamate Cognition Recognition memory
(Metabotropic glutamate receptor type 2/3)
(Novel object recognition)
(Pre-pulse inhibition of acoustic startle)
(Conditioned emotional response)
(Analysis of variance)
- Andreasen NC (1995) Symptoms, signs and diagnosis of schizophrenia. Lancet 346:477–481Google Scholar
- Brown MW, Aggleton JP (2001) Recognition memory: What are the roles of the perirhinal cortex and hippocampus? Nat Rev Neurosci 2:51–61Google Scholar
- Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD (2000d) The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3, 4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat. J Neurochem 75:1147–1154CrossRefGoogle Scholar
- Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD (2001) Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 40:847–855PubMedCrossRefGoogle Scholar
- Eichenbaum H, Yonelinas AP, Ranganath C (2007) The medial temporal lobe and recognition memory. Annu Rev Neurosci 30:123–152Google Scholar
- Fell MJ, Perry KW, Falcone JF, Johnson BG, Barth VN, Rash KS, Lucaites VL, Threlkeld PG, Monn JA, McKinzie DL, Marek GJ, Svensson KA, Nelson DL (2009) In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S, 2S, 5R, 6S-2-aminobicyclo[3.1.0]hexane-2, 6-bicaroxylate monohydrate (LY354740) and (−)-2-oxa-4-aminobicyclo[3.1.0] hexane-4, 6-dicarboxylic acid (LY379268). J Pharmacol Exp Ther 331:1126–1136PubMedCrossRefGoogle Scholar
- Galici R, Echemendia NG, Rodriguez AL, Conn PJ (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315:1181–1187PubMedCrossRefGoogle Scholar
- Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 179:303–309PubMedCrossRefGoogle Scholar
- Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR, Grutsch JL, Wright RA, Johnson BG, Andis SL, Kingston A, Tomlinson R, Lewis R, Griffey KR, Tizzano JP, Schoepp DD (1999) Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0]hexane-2, 6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 42:1027–1040PubMedCrossRefGoogle Scholar
- Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004) Identification of seperable cognitive factors in schizophrenia. Schizophr Res 72:29–39Google Scholar
- Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102–1107PubMedCrossRefGoogle Scholar
- Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD (2007) Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (−)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4, 6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 321:308–317PubMedCrossRefGoogle Scholar
- Schlumberger C, SchÃ¤fer D, Barberi C, MorÃ¨ L, Nagel J, Pietraszek M, Schmidt WJ, Danysz W (2009) Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav Pharmacol 20:56–66. doi:10.1097/FBP.0b013e3283242f57 PubMedCrossRefGoogle Scholar